Akari Therapeutcis (AKTX) Announces Cooperative Research and Development Agreement with USAISR for Nomacopan in Trauma
- S&P 500, Dow climb for third day and close at records
- Tesla (TSLA) China Numbers 'Robust' - Wedbush
- Apple (AAPL) Shares Seen as 'Attractive' as Recent Checks Show Continuously Strong Demand - Citi
- Amazon.com warehouse workers vote to reject forming union in Alabama
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced a cooperative research and development agreement (CRADA) with the U S. Army Institute of Surgical Research (USAISR), working to evaluate the potential for use of nomacopan in civilian and battlefield trauma for which there are currently no approved therapies.
Dr Miles Nunn, Chief Scientific Officer of Akari Therapeutics said, “Nomacopan has shown encouraging results in trauma-related conditions including traumatic brain injury1, immune complex-induced acute lung injury2, myocardial infarction3 and blast injury. The dual inhibition of C5 and LTB4 by nomacopan for the treatment of trauma is supported by a large body of literature4 reflecting the harmful role for both these inflammatory mediators in the early pathophysiology of trauma and haemorrhagic shock.”
Akari has established a collaboration with the USAISR via a CRADA to evaluate the activity of nomacopan in preclinical trauma and haemorrhagic shock models.
Trauma is a global burden disease in civilians and service members and is the leading cause of death for individuals up to the age of 45 years. Annual total U.S. inpatient trauma-related hospital costs are approximately $30 billion5. In the U.S. there are approximately 500,000 trauma hospital discharges a year which are defined as severe and might benefit from early drug intervention to reduce multi-organ dysfunction following trauma.
Nomacopan’s unique dual binding of C5 and LTB4 targets the adverse inflammatory roles of both the complement and leukotriene pathways in trauma for which there are no currently approved therapies. The secondary neuroinflammation and neuronal damage that follows the primary traumatic injury is an important cause of morbidity in affected people and the role of both the leukotriene and complement pathways are well documented in trauma, which underpins the potential therapeutic benefit of the dual action of nomacopan.
The ongoing work with nomacopan is focused on preliminary evaluations of biological effects in large animal trauma models. Additional studies will be required to establish the safety and biological activity of nomacopan in contaminated wound models relevant to battlefield conditions. Nomacopan does not require special handling, can be carried in small vials and can be quickly reconstituted in small volumes of fluid, which may facilitate its use in prehospital settings.
Clive Richardson, Chief Executive Officer of Akari Therapeutics said, “There are currently no drugs approved for trauma to improve survival and recovery. With nomacopan, Akari’s goal is to make a significant contribution to trauma recovery for the benefit of the U.S. armed forces as well as to the wider civilian population.”
1) (Fluiter et al., 2014),2) (Roversi et al., 2013)3) (Pischke et al., 2017)4) (Sadik et al., 2018; Auner et al., 2012; Li et al., 2019; Yang et al., 2019; Rittirsch et al., 2012; Störmann et al., 2017; Tanaka et al., 1997; Brady et al., 1992; Solomkin 1990)5) (DiMaggio et al., 2016)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Genmab A/S (GMAB) and Seagen (SGEN) Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin BLA for Patients with Recurrent or Metastatic Cervical Cancer
- Iovance Biotherapeutics (IOVA) Announces Clinical Data Updates for Lifileucel in Advanced Melanoma During AACR
- Surface Oncology (SURF) Presents Promising Preclinical Data for Lead Immunotherapy Product Candidates at AACR